Tianda Pharmaceuticals Limited (HKG:0455)
Hong Kong · Delayed Price · Currency is HKD 0.1080
0.00 (0.00%)
At close: Feb 13, 2026
Tianda Pharmaceuticals Revenue
Tianda Pharmaceuticals had revenue of 136.64M HKD in the half year ending June 30, 2025, a decrease of -54.98%. This brings the company's revenue in the last twelve months to 310.50M, down -19.28% year-over-year. In the year 2024, Tianda Pharmaceuticals had annual revenue of 329.94M, down -37.99%.
Revenue (ttm)
310.50M
Revenue Growth
-19.28%
P/S Ratio
0.75
Revenue / Employee
497.59K
Employees
624
Market Cap
232.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 329.94M | -202.15M | -37.99% |
| Dec 31, 2023 | 532.09M | -14.61M | -2.67% |
| Dec 31, 2022 | 546.69M | 36.74M | 7.20% |
| Mar 31, 2022 | 509.96M | 35.62M | 7.51% |
| Mar 31, 2021 | 474.33M | -17.14M | -3.49% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhongzhi Pharmaceutical Holdings | 2.20B |
| Shenzhen Neptunus Interlong Bio-technique Company | 1.09B |
| Kontafarma China Holdings | 891.73M |
| Wai Yuen Tong Medicine Holdings | 721.27M |
| PuraPharm Corporation | 346.76M |
| Fusen Pharmaceutical Company | 264.08M |
| Pak Fah Yeow International | 199.55M |
| Extrawell Pharmaceutical Holdings | 52.65M |